Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CTI BIOPHARMA CORP.

(CTIC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

CTI BioPharma Shares Slide as FDA Extends Pacritinib Review

12/01/2021 | 11:11am EST

By Colin Kellaher

Shares of CTI BioPharma Corp. fell nearly 20% on Wednesday after the U.S. Food and Drug Administration extended its review of the company's application seeking approval of pacritinib, its lead product candidate, in certain patients with the bone-marrow cancer myelofibrosis.

The Seattle biopharmaceutical company said the delay comes after it recently submitted additional clinical data in the course of product labeling discussions with the FDA.

CTI said the agency, which had previously granted priority review to the application with a target action date of Nov. 30, determined that the submission constitutes a major amendment to the application and extended the target action date to Feb. 28, 2022, to allow for a full review of the submission.

Analysts at Stifel said they still model an 85% probability of approval for pacritinib, adding that they believe the delay has more to do with the FDA needing more review time than it does with any potential shortcoming in the pacritinib data.

CTI, which is seeking approval of pacritinib for the treatment of adults with intermediate or high-risk primary or secondary myelofibrosis, noted that it isn't aware of any major deficiencies in the application.

Stifel, which has a "buy" rating and a $5.50 target price on CTI shares, said it remains bullish and recommends investors take advantage of the pullback in the stock.

CTI shares were recently down 18%, to $1.845, just above a 52-week low of $1.835 hit earlier in the session.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

12-01-21 1110ET

All news about CTI BIOPHARMA CORP.
01/06CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR
2021From key drug updates to ASH 2021, the MPN Hub continues to enhance global knowledge of..
AQ
2021CTI BioPharma to Present at the JMP Securities Hematology & Oncology Summit on Monday, ..
PR
2021Top Midday Decliners
MT
2021CTI BioPharma Stock Slump Continues into Second Day as FDA Extends Myelofibrosis Drug R..
MT
2021CTI BioPharma Shares Slide as FDA Extends Pacritinib Review
DJ
2021Needham Adjusts Price Target on CTI BioPharma to $5 From $6, Maintains Buy Rating
MT
2021CTI BioPharma Says US FDA Pushes Back Pacritinib Action Date by 3 Months; Shares Slump ..
MT
2021CTI BioPharma Announces Extension of FDA Review Period for Pacritinib in Myelofibrosis ..
PR
2021CTI BioPharma Corp. Announces Extension of FDA Review Period for Pacritinib in Myelofib..
CI
More news
Analyst Recommendations on CTI BIOPHARMA CORP.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -89,3 M - -
Net cash 2021 5,70 M - -
P/E ratio 2021 -2,21x
Yield 2021 -
Capitalization 214 M 214 M -
EV / Sales 2021 -
EV / Sales 2022 5,25x
Nbr of Employees 23
Free-Float -
Chart CTI BIOPHARMA CORP.
Duration : Period :
CTI BioPharma Corp. Technical Analysis Chart | CTIC | US12648L6011 | MarketScreener
Technical analysis trends CTI BIOPHARMA CORP.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 2,21 $
Average target price 7,28 $
Spread / Average Target 230%
EPS Revisions
Managers and Directors
Adam R. Craig President, CEO, Chief Medical Officer & Director
David H. Kirske Chief Financial Officer & Executive Vice President
Laurent Fischer Chairman
Bruce J. Seeley Chief Operating Officer & Executive Vice President
Reed Vaughn Tuckson Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
CTI BIOPHARMA CORP.-10.89%214
MODERNA, INC.-36.98%64 900
LONZA GROUP AG-15.65%52 307
IQVIA HOLDINGS INC.-14.60%46 031
SEAGEN INC.-17.50%23 323
ICON PUBLIC LIMITED COMPANY-18.65%20 508